Cargando…
Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
BACKGROUND: Hypofractionated stereotactic body radiation therapy (SBRT) has been advanced as monotherapy for low-risk prostate cancer. We examined the dose distributions and early clinical outcomes using this modality for the treatment of intermediate-risk prostate cancer. METHODS: Forty-one sequent...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570380/ https://www.ncbi.nlm.nih.gov/pubmed/23369294 http://dx.doi.org/10.1186/1748-717X-8-30 |
_version_ | 1782259060993687552 |
---|---|
author | Ju, Andrew W Wang, Hongkun Oermann, Eric K Sherer, Benjamin A Uhm, Sunghae Chen, Viola J Pendharkar, Arjun V Hanscom, Heather N Kim, Joy S Lei, Siyuan Suy, Simeng Lynch, John H Dritschilo, Anatoly Collins, Sean P |
author_facet | Ju, Andrew W Wang, Hongkun Oermann, Eric K Sherer, Benjamin A Uhm, Sunghae Chen, Viola J Pendharkar, Arjun V Hanscom, Heather N Kim, Joy S Lei, Siyuan Suy, Simeng Lynch, John H Dritschilo, Anatoly Collins, Sean P |
author_sort | Ju, Andrew W |
collection | PubMed |
description | BACKGROUND: Hypofractionated stereotactic body radiation therapy (SBRT) has been advanced as monotherapy for low-risk prostate cancer. We examined the dose distributions and early clinical outcomes using this modality for the treatment of intermediate-risk prostate cancer. METHODS: Forty-one sequential hormone-naïve intermediate-risk prostate cancer patients received 35–36.25 Gy of CyberKnife-delivered SBRT in 5 fractions. Radiation dose distributions were analyzed for coverage of potential microscopic ECE by measuring the distance from the prostatic capsule to the 33 Gy isodose line. PSA levels, toxicities, and quality of life (QOL) measures were assessed at baseline and follow-up. RESULTS: All patients completed treatment with a mean coverage by the 33 Gy isodose line extending >5 mm beyond the prostatic capsule in all directions except posteriorly. Clinical responses were documented by a mean PSA decrease from 7.67 ng/mL pretreatment to 0.64 ng/mL at the median follow-up of 21 months. Forty patients remain free from biochemical progression. No Grade 3 or 4 toxicities were observed. Mean EPIC urinary irritation/obstruction and bowel QOL scores exhibited a transient decline post-treatment with a subsequent return to baseline. No significant change in sexual QOL was observed. CONCLUSIONS: In this intermediate-risk patient population, an adequate radiation dose was delivered to areas of expected microscopic ECE in the majority of patients. Although prospective studies are needed to confirm long-term tumor control and toxicity, the short-term PSA response, biochemical relapse-free survival rate, and QOL in this interim analysis are comparable to results reported for prostate brachytherapy or external beam radiotherapy. TRIAL REGISTRATION: The Georgetown Institutional Review Board has approved this retrospective study (IRB 2009–510). |
format | Online Article Text |
id | pubmed-3570380 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35703802013-02-13 Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer Ju, Andrew W Wang, Hongkun Oermann, Eric K Sherer, Benjamin A Uhm, Sunghae Chen, Viola J Pendharkar, Arjun V Hanscom, Heather N Kim, Joy S Lei, Siyuan Suy, Simeng Lynch, John H Dritschilo, Anatoly Collins, Sean P Radiat Oncol Research BACKGROUND: Hypofractionated stereotactic body radiation therapy (SBRT) has been advanced as monotherapy for low-risk prostate cancer. We examined the dose distributions and early clinical outcomes using this modality for the treatment of intermediate-risk prostate cancer. METHODS: Forty-one sequential hormone-naïve intermediate-risk prostate cancer patients received 35–36.25 Gy of CyberKnife-delivered SBRT in 5 fractions. Radiation dose distributions were analyzed for coverage of potential microscopic ECE by measuring the distance from the prostatic capsule to the 33 Gy isodose line. PSA levels, toxicities, and quality of life (QOL) measures were assessed at baseline and follow-up. RESULTS: All patients completed treatment with a mean coverage by the 33 Gy isodose line extending >5 mm beyond the prostatic capsule in all directions except posteriorly. Clinical responses were documented by a mean PSA decrease from 7.67 ng/mL pretreatment to 0.64 ng/mL at the median follow-up of 21 months. Forty patients remain free from biochemical progression. No Grade 3 or 4 toxicities were observed. Mean EPIC urinary irritation/obstruction and bowel QOL scores exhibited a transient decline post-treatment with a subsequent return to baseline. No significant change in sexual QOL was observed. CONCLUSIONS: In this intermediate-risk patient population, an adequate radiation dose was delivered to areas of expected microscopic ECE in the majority of patients. Although prospective studies are needed to confirm long-term tumor control and toxicity, the short-term PSA response, biochemical relapse-free survival rate, and QOL in this interim analysis are comparable to results reported for prostate brachytherapy or external beam radiotherapy. TRIAL REGISTRATION: The Georgetown Institutional Review Board has approved this retrospective study (IRB 2009–510). BioMed Central 2013-01-31 /pmc/articles/PMC3570380/ /pubmed/23369294 http://dx.doi.org/10.1186/1748-717X-8-30 Text en Copyright ©2013 Ju et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Ju, Andrew W Wang, Hongkun Oermann, Eric K Sherer, Benjamin A Uhm, Sunghae Chen, Viola J Pendharkar, Arjun V Hanscom, Heather N Kim, Joy S Lei, Siyuan Suy, Simeng Lynch, John H Dritschilo, Anatoly Collins, Sean P Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer |
title | Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer |
title_full | Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer |
title_fullStr | Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer |
title_full_unstemmed | Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer |
title_short | Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer |
title_sort | hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570380/ https://www.ncbi.nlm.nih.gov/pubmed/23369294 http://dx.doi.org/10.1186/1748-717X-8-30 |
work_keys_str_mv | AT juandreww hypofractionatedstereotacticbodyradiationtherapyasmonotherapyforintermediateriskprostatecancer AT wanghongkun hypofractionatedstereotacticbodyradiationtherapyasmonotherapyforintermediateriskprostatecancer AT oermannerick hypofractionatedstereotacticbodyradiationtherapyasmonotherapyforintermediateriskprostatecancer AT shererbenjamina hypofractionatedstereotacticbodyradiationtherapyasmonotherapyforintermediateriskprostatecancer AT uhmsunghae hypofractionatedstereotacticbodyradiationtherapyasmonotherapyforintermediateriskprostatecancer AT chenviolaj hypofractionatedstereotacticbodyradiationtherapyasmonotherapyforintermediateriskprostatecancer AT pendharkararjunv hypofractionatedstereotacticbodyradiationtherapyasmonotherapyforintermediateriskprostatecancer AT hanscomheathern hypofractionatedstereotacticbodyradiationtherapyasmonotherapyforintermediateriskprostatecancer AT kimjoys hypofractionatedstereotacticbodyradiationtherapyasmonotherapyforintermediateriskprostatecancer AT leisiyuan hypofractionatedstereotacticbodyradiationtherapyasmonotherapyforintermediateriskprostatecancer AT suysimeng hypofractionatedstereotacticbodyradiationtherapyasmonotherapyforintermediateriskprostatecancer AT lynchjohnh hypofractionatedstereotacticbodyradiationtherapyasmonotherapyforintermediateriskprostatecancer AT dritschiloanatoly hypofractionatedstereotacticbodyradiationtherapyasmonotherapyforintermediateriskprostatecancer AT collinsseanp hypofractionatedstereotacticbodyradiationtherapyasmonotherapyforintermediateriskprostatecancer |